Start Here: The ReProgram | Longevity Science Without the Hype

🎬 EPISODE OVERVIEWDoes resveratrol live up to the longevity hype? We examine the clinical data to see if it actually improves health markers.Research into this supplement often focuses on molecular changes, but we look at how resveratrol impacts real-world patient outcomes. By analyzing studies on cardiovascular health, inflammation, and cognitive function, we distinguish between theoretical benefits and proven clinical results. This scorecard provides a clear framework for evaluating whether the current evidence justifies its use as a longevity intervention.We also compare how different patient groups respond to this compound, highlighting where the data remains inconclusive. Understanding these limitations is essential for anyone trying to separate marketing claims from rigorous science. This analysis is for those who prioritize evidence-based health decisions over popular trends.If you value longevity science without the hype, subscribe to The ReProgram.🔑 KEYWORDSResveratrol • Longevity • Human Trials • Healthy Aging • Evidence Scorecard • Supplements📌 KEY TAKEAWAYS• Changes in selected markers do not establish longer human life.• Study population, dose and outcome shape what a finding means.• Better cognitive test scores do not demonstrate dementia prevention.• Natural origin does not settle safety or medication interactions.• Ask what was measured, in whom, and whether the benefit matters.🎙️ THE REPROGRAM PERSPECTIVEA molecule can be biologically interesting while its value as an everyday supplement remains uncertain. We should be able to hold both ideas at once. The score can change when the evidence changes.⏱️ CHAPTERS00:00 Resveratrol and its claims01:09 How the scorecard works02:04 Biology and the early animal studies03:38 Absorption and exposure04:08 Metabolic markers05:52 Cardiovascular claims06:36 The exercise trial07:39 Cognition and dementia distinctions09:40 Inflammatory markers11:08 Human lifespan12:01 Safety and drug interactions13:36 The final scorecard and C− grade14:40 What better evidence would look like14:56 Three questions for any longevity claim📝 NOTES AND REFERENCESBaur et al. (2006), high-calorie-diet mice:https://doi.org/10.1038/nature05354Miller et al. (2011), mouse lifespan:https://doi.org/10.1093/gerona/glq178Timmers et al. (2011), metabolic study:https://doi.org/10.1016/j.cmet.2011.10.002Yoshino et al. (2012), nonobese women:https://doi.org/10.1016/j.cmet.2012.09.015Sun et al. (2026), umbrella review:https://doi.org/10.1186/s12937-026-01319-5Gliemann et al. (2013), exercise trial:https://pubmed.ncbi.nlm.nih.gov/23878368/Thaung Zaw et al. (2021), cognition crossover trial:https://doi.org/10.1016/j.clnu.2020.08.025Wightman et al. (2026), cognition review:https://doi.org/10.3389/fnut.2026.1839709RESET / JOTROL trial: investigational formulation, not an efficacy result:https://clinicaltrials.gov/study/NCT07592767Zhu et al. (2025), inflammatory markers:https://doi.org/10.3389/fendo.2024.1463027Brown et al. (2010), repeated-dose safety:https://doi.org/10.1158/0008-5472.CAN-10-2364Chow et al. (2010), drug-metabolizing enzymes:https://doi.org/10.1158/1940-6207.CAPR-09-0155💬 JOIN THE CONVERSATIONWhich result would most change your view of resveratrol: better function, fewer clinical events, or longer life? Tell us why.Subscribe for longevity biology without the hype:https://www.youtube.com/@ReProgramPodcastMechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEWCan we reverse aging? We examine what recent clinical announcements actually prove about the state of human longevity science.Recent reports regarding partial cellular reprogramming have sparked debate about the potential for human age reversal. We break down the distinction between clinical benefit and actual tissue rejuvenation, focusing on what early findings from human trials really indicate. By separating marketing claims from biological reality, we clarify how these interventions affect cellular function.Understanding the limits of current research is vital for anyone interested in healthy aging. We analyze why improvements in specific metrics, such as visual-field tests, do not necessarily equate to a universal reset of the aging process. This assessment provides a grounded look at how we measure progress in the field of longevity and what future experiments must demonstrate to validate these early observations.If you value longevity science without the hype, subscribe to The ReProgram.🔑 KEYWORDSPartial Reprogramming • ER-100 • OSK • Epigenetics • Glaucoma • Cell Identity • Aging Clocks • Healthspan📌 KEY TAKEAWAYS• Partial reprogramming aims to change cellular state while preserving specialized function.• Early observations in three participants justify further study, not a conclusion of human age reversal.• Improvement at visual-field test locations is not a percentage gain in overall vision.• Control of gene expression does not establish that every downstream effect is reversible.• Durable patient benefit, controlled comparisons, and replication matter more than a younger-looking test alone.🎙️ THE REPROGRAM PERSPECTIVEA treatment can be a major medical advance without proving that aging has been reversed.The goal is useful function, resilience, and more time living well. Hope and demanding scientific questions belong together.⏱️ CHAPTERS00:00 Can we reverse aging—and what would count?01:30 The ReProgram opening01:38 Partial reprogramming and the evidence cutoff02:18 Cell identity and the epigenome03:22 Yamanaka factors and pluripotency04:23 The challenge of partial reprogramming05:16 What mouse studies establish06:01 Beyond a universal reset button06:51 Vision, OSK, and preclinical evidence08:42 ER-100 and early human observations10:30 Understanding the visual-field measurement11:49 What a small early trial can tell us12:50 Variability, learning, and alternative explanations15:39 Cell identity and safety16:16 Delivery, control, and reversibility17:32 Company announcements and complete evidence18:05 Clinical benefit versus tissue rejuvenation19:56 Broader healthspan claims20:35 Aging clocks and meaningful outcomes22:27 What would strengthen the evidence?24:26 Hope, rigor, and the next experiments25:23 Closing thoughts and subscribe📝 NOTES AND REFERENCES1. Takahashi & Yamanaka. Induction of pluripotent stem cells (Cell, 2006).https://doi.org/10.1016/j.cell.2006.07.0242. Ocampo et al. In vivo partial reprogramming (Cell, 2016).https://doi.org/10.1016/j.cell.2016.11.0523. Lu et al. Reprogramming to recover youthful epigenetic information and restore vision (Nature, 2020).https://doi.org/10.1038/s41586-020-2975-44. Life Biosciences. Interim company announcement, October 8, 2026; preliminary findings, not a full trial publication.https://www.lifebiosciences.com/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies/5. ER-100 trial registration, NCT07290244.https://clinicaltrials.gov/study/NCT07290244💬 JOIN THE CONVERSATIONWhat evidence would convince YOU that a treatment meaningfully rejuvenated human tissue—and what should the next study measure?Subscribe to The ReProgram for longevity biology without the hype.https://www.youtube.com/@ReProgramPodcastMechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEWCan you actually eat like a centenarian to extend your life? We examine the evidence behind dietary habits and aging.Dr. Paola Sebastiani joins us to discuss the complexities of longevity science and why the current diet of someone who has lived to 100 may not reflect the factors that helped them reach that age. We unpack how metabolomics provides clues about physiological decline, while emphasizing that a single blood marker does not establish cause and effect for long-term health.Our conversation addresses common myths regarding protein intake and the role of genetics in exceptional longevity. By analyzing the data from the New England Centenarian Study, we separate biological mechanisms from marketing claims to understand what truly supports healthy aging. We also look at the limitations of biological age tests and why standardization remains a critical challenge in current research.If you value longevity science without the hype, subscribe to The ReProgram for weekly evidence-based breakdowns. What is one belief about food and aging you would be willing to reconsider?👤 ABOUT THE SPEAKERDr. Paola Sebastiani is a Professor at Tufts University School of Medicine and Director of the Tufts CTSI Biostatistics, Epidemiology, and Research Design Center. A biostatistician studying genetics and exceptional longevity, she and her group lead data analyses for the New England Centenarian Study.Official profile: https://disc.tufts.edu/paola-sebastiani🔑 KEYWORDSPaola Sebastiani • Centenarians • Nutrition • Metabolomics • Protein • Healthy Aging • Longevity Genetics • Biological Age📌 KEY TAKEAWAYS• Metabolites offer clues about aging, but a blood marker does not by itself establish cause and effect.• A centenarian’s current diet may differ from the diet they followed decades earlier. Longitudinal studies matter.• Protein findings from animal studies do not automatically translate to older adults. Sebastiani also cautions against assuming more is always better.• Centenarians are a diverse group; no single food or genetic explanation captures every path to exceptional longevity.• Sebastiani emphasizes standardization and interpretation when discussing biological-age tests.🎙️ THE REPROGRAM PERSPECTIVEA longevity headline can turn an association into an apparent prescription. We need to ask who was studied, what was measured, and whether a finding predicts better health or simply accompanies it.The goal is to preserve health, function, and independence—not just chase a number.⏱️ CHAPTERS00:00 Should we eat like a centenarian?00:58 Introducing Paola Sebastiani01:57 An unexpected route into longevity research03:56 The Cell Reports paper and metabolomics06:04 Nutrition and the dark-chocolate connection07:19 Why following people over time matters09:01 Essential amino acids and dietary changes14:12 What do centenarians eat?18:31 Protein restriction versus aging well20:39 Protein sources and pumpkin seeds22:40 Dietary fats23:26 Genes, nutrition, and longevity families26:57 Centenarian misconceptions27:43 Biological-age tests28:57 Healthspan and longevity interventions30:05 The unresolved genetics of longevity31:08 Activity tracking and personal habits33:21 What aging well means34:20 Closing thoughts📝 NOTES AND REFERENCES1. Sebastiani P et al. Metabolite signatures of chronological age, aging, survival, and longevity. Cell Reports (2024);43(11):114913.https://doi.org/10.1016/j.celrep.2024.114913Open-access paper: https://pmc.ncbi.nlm.nih.gov/articles/PMC11656345/💬 JOIN THE CONVERSATIONWhat is one belief about food and aging you would be willing to reconsider?Subscribe to The ReProgram for more conversations about livingwell.https://www.youtube.com/@ReProgramPodcastLongevity Biology Without the HypeMechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEWDoes your fish oil capsule deserve its reputation? In Episode 31, I review omega-3s for heart health, cognition, and healthy aging, then give five evidence scores and an overall C+.We examine VITAL, REDUCE-IT, STRENGTH, newer DHA research, aging clocks, and safety. Eating fish, taking supplements, and using prescription omega-3s are different questions.🔑 KEYWORDSOmega-3 • Fish Oil • EPA • DHA • Triglycerides • Cognition • Aging Clocks • Atrial Fibrillation • Longevity📌 KEY TAKEAWAYS• Triglyceride lowering: 5/5 at studied therapeutic doses.• Routine cardiovascular prevention in generally healthy adults: 2/5. Prescription EPA in selected high-risk patients is a separate clinical decision.• Preventing cognitive decline in generally healthy older adults: 1/5.• Epigenetic aging clocks: 2/5. Small changes in clock estimates do not establish longer life.• Extending human lifespan through routine supplementation: 1/5.• Overall: C+ for routine OTC fish oil as a healthy-aging intervention; this is my assessment, not a mathematical average. Dose, formulation, and baseline risk matter.🎙️ THE REPROGRAM PERSPECTIVEA biological mechanism or improved test result is a starting point. Ask whether the evidence shows better health, function, or survival in people like you. Educational discussion; understand prescribed treatment with your clinician before making changes.⏱️ CHAPTERS00:00 What has fish oil earned?00:55 The Scorecard framework01:16 Fish, supplements, and prescription products01:56 Read the EPA and DHA label02:27 Triglycerides: the strongest evidence03:43 VITAL and heart prevention04:39 REDUCE-IT and prescription EPA05:50 STRENGTH and conflicting results07:08 Brain health and the DHA trials08:34 DO-HEALTH and aging clocks09:59 Heart-rhythm risk and interactions11:37 Five claims, five scores13:22 The C+ verdict and its limits14:27 Questions to ask about your supplement15:31 Closing perspective💬 JOIN THE CONVERSATIONIf you take fish oil, what benefit are you hoping for—and does the evidence match that goal?Subscribe to The ReProgram: https://www.youtube.com/@ReProgramPodcastLongevity Biology Without the Hype.Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEWCan a younger clock score translate into better health?In Episode 30, I sit down with Dr. Steve Horvath to explore epigenetic clocks, biological-age claims, and his vision for rejuvenation.We discuss why there are so many clocks, what stands between research and patient care, prevention, and why progress may come one organ at a time.👤 ABOUT THE SPEAKERDr. Steve Horvath is Professor of Medicine and Director of Aging Biology Research at UCLA’s David Geffen School of Medicine. A geroscientist and biostatistician, he developed the influential 2013 multi-tissue DNA methylation clock.Lab profile: https://horvathaginglab.org/🔑 KEYWORDSSteve Horvath • Epigenetic Clocks • DNA Methylation • Biological Age • Rejuvenation • Prevention • Aging Biomarkers • Geroscience📌 KEY TAKEAWAYS• Different aging clocks can produce different results. Horvath argues for transparent reporting across multiple clocks.• Dramatic age-reversal claims deserve scrutiny; a younger test result needs meaningful interpretation.• Horvath sees promise in clinical use, while emphasizing that routine patient care is not there yet.• Rejuvenation is connected to prevention: the aim is to preserve health before disease develops.• A realistic path may focus on individual organs rather than a single treatment for the entire body.🎙️ THE REPROGRAM PERSPECTIVEBetter measurement can sharpen the questions we ask about aging. The next challenge is connecting those measurements to outcomes that matter to people.Our focus: what changed, how reliably was it measured, and what does it mean for health and function?⏱️ CHAPTERS00:00 Can we measure and reverse aging?00:51 Introducing Steve Horvath01:40 Reinventing a research career05:28 Why are there so many aging clocks?07:51 Bringing clocks into clinical practice09:16 Evaluating age-reversal claims11:31 Rejuvenation and prevention14:37 What does rejuvenation mean?16:26 One organ at a time18:36 Lifestyle, testing, and perspective20:57 Closing thoughts📝 NOTES AND REFERENCESRelated papers featured in the edit:1. Horvath S. DNA methylation age of human tissues and cell types. Genome Biology (2013).https://doi.org/10.1186/gb-2013-14-10-r1152. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nature Reviews Genetics (2018).https://doi.org/10.1038/s41576-018-0004-33. Lu Y et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature (2020).https://doi.org/10.1038/s41586-020-2975-4The Lu study is preclinical mouse research, not evidence of whole-body age reversal in humans.💬 JOIN THE CONVERSATIONWhat would convince you that an intervention truly rejuvenates: a younger clock score, better organ function, or both?Subscribe to The ReProgram for longevity biology without the hype.https://www.youtube.com/@ReProgramPodcastMechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEWWhy do some animals live so much longer than others—and what can they teach us about healthier human aging?In Episode 29 of The ReProgram, I sit down with Dr. Steve Austad to explore nature’s longevity clues, why women tend to outlive men, and what would count as convincing evidence that an intervention slows aging.We discuss aging “speedometers,” the difference between lifespan and healthspan, the case for funding geroscience, and how to evaluate biological-age claims without losing sight of enjoying life.👤 ABOUT THE SPEAKERDr. Steven N. Austad is a Distinguished Professor and Protective Life Endowed Chair in Healthy Aging Research at the University of Alabama at Birmingham, and Scientific Director of the American Federation for Aging Research. His research explores the comparative biology of aging, using differences among species to understand longevity and identify potential ways to preserve human health.Official profile: https://www.uab.edu/icar/about/icar-leadership/steven-n-austad-phd🔑 KEYWORDSLongevity • Comparative Biology • Steve Austad • Healthspan • Aging Rate Indicators • Biological Age • Geroscience • Sex Differences • DunedinPACE📌 KEY TAKEAWAYS• Long-lived animals offer clues about aging biology and potential directions for human research.• A finding in animals is a starting point; demonstrating a meaningful benefit in people requires further testing.• Measuring biological age and measuring the pace of aging are different questions. A change in a test result alone does not prove that an intervention slows aging.• Healthspan puts the focus on maintaining function and quality of life.• Evaluating longevity claims means asking what was measured, what changed, and whether the evidence supports the conclusion.🎙️ THE REPROGRAM PERSPECTIVENature shows that the pace of aging varies enormously across species. Understanding the biology behind those differences could reveal ways to preserve human health.For The ReProgram, the next step is to connect those clues to rigorous tests: does an intervention produce a reproducible improvement in function, resilience, or healthy years of life? Aging measurements are valuable when they help answer that question. The goal is more time living well, with evidence strong enough to guide our choices.⏱️ CHAPTERS00:00 What nature can teach us00:28 The ReProgram00:36 Introducing Steve Austad01:23 Opossums and the origins of an aging scientist02:44 What is aging?03:43 Evolution and longevity04:46 Learning from long-lived animals07:24 Why women tend to live longer12:03 What would count as evidence of slower aging?13:13 From animal findings to human benefits14:31 Aging clocks versus aging speedometers18:49 Lifespan and healthspan19:44 Lightning round: the XPRIZE21:19 Funding aging research22:43 Evaluating biological-age claims24:01 Enjoying life while studying longevity25:13 Closing thoughts📝 NOTES AND REFERENCES1. Austad SN, Kaeberlein M, Miller RA. Aging rate indicators and the search for anti-aging drugs. Frontiers in Science (2026).https://doi.org/10.3389/fsci.2026.18213932. Belsky DW et al. DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife (2022);11:e73420.https://doi.org/10.7554/eLife.73420Clarification: DunedinPACE uses DNA methylation to estimate the pace of aging. The on-screen explanation clarifies the interview’s reference to an RNA marker.3. XPRIZE Healthspan — official competition information:https://www.xprize.org/competitions/healthspan💬 JOIN THE CONVERSATIONWhat would convince YOU that a treatment truly slows aging: a biological-age test, better physical function, or something else? Tell us which result matters most—and why.If you value longevity science without the hype, subscribe to The ReProgram.https://www.youtube.com/@ReProgramPodcastMechanism over marketing. Evidence over anecdotes. Trade-offs over hype.

🎬 EPISODE OVERVIEWThe Longevity Consortium is mapping the biology of aging. We review the NIH-funded research aiming to delay chronic disease.The NIH-supported Longevity Consortium is a massive effort to understand the biology of aging to reduce risks of cancer, dementia, and frailty. We examine their five core focus areas, ranging from exceptional longevity cohorts to candidate drug screening. Dr. Nik Schork and Dr. George Murphy break down the current strategy for targeting age-related decline.This initiative represents a distinct pivot in geroscience research, moving beyond single-pathway hypotheses to look at systemic biological markers. We analyze the scope of these projects to see which are likely to yield clinical outcomes and which remain preliminary explorations. Understanding the biology of aging remains a complex challenge, but this consortium provides a structural framework for how we might eventually mitigate chronic disease.🔑 KEYWORDSLongevity • Healthspan • Aging Biology • NIH • NIA • Longevity Consortium • Nik Schork • Centenarians • Human Cell Models • Geroscience📌 KEY TAKEAWAYS◆ Healthspan and lifespan are related goals, but improving a biological measurement is not the same as proving that people live longer.◆ Exceptional longevity may reflect protective biology alongside disease-risk variants, as well as behavior and environmental exposures.◆ The five projects connect discovery with functional testing. A genetic association still needs a biological explanation and follow-up experiments.◆ Human cell models help isolate a signal; animal studies and human research test whether it matters in a more complex system.◆ Public funding supports collaboration across disciplines and exploratory work that may not begin with a single commercial product.◆ Shared aging mechanisms could offer opportunities to address multiple diseases. That is a research goal, not a claim that a proven universal treatment exists.◆ A critical approach to evidence matters when evaluating claims about measuring or reversing biological age.🎙️ THE REPROGRAM PERSPECTIVELongevity Biology Without the Hype. The important question is not simply whether an intervention changes a marker, but whether it produces a meaningful, reproducible benefit for people. This conversation follows the research pathway; it does not present a finished anti-aging treatment.⏱️ CHAPTERS00:00 Can we slow aging?01:08 Meet Dr. Nik Schork02:01 From philosophy to longevity science03:53 What is the Longevity Consortium?05:24 Healthspan versus lifespan06:31 Why team science matters07:55 Project 1: Predicting human longevity09:23 Project 2: Lessons from long-lived species12:46 Project 3: Centenarians and resilience14:50 Disease-risk genes and exceptional longevity16:20 Project 4: From genes to candidate drugs19:04 Project 5: Testing ideas in human cells21:42 Connecting a discovery across the consortium24:45 The challenge of proving human benefit26:38 What public funding makes possible29:12 Shared aging mechanisms and the public payoff32:13 What success could look like35:02 Lightning round: Can aging biology be modified?36:12 Misconceptions about publicly funded science37:24 How to evaluate longevity claims39:13 How the science shapes Nik’s own health choices41:50 Closing the conversation42:48 The ReProgram takeaway📝 SELECTED NOTES AND REFERENCES1. Longevity Consortium overview. Official description of the research program and its integrated approach.https://www.longevityconsortium.org/overview/2. Longevity Consortium projects and resources. Explore the five projects and their leadership. https://www.longevityconsortium.org/▶ Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

🎬 EPISODE OVERVIEWCould the compound in magic mushrooms influence how we age? Psilocybin research is producing intriguing findings, but changing brain activity, treating depression and extending human life are very different claims.In Episode 27, Dr. George Murphy puts psilocybin through The ReProgram Scorecard. He examines experiments in human cells and aged mice, brain imaging and plasticity studies, inflammatory markers, and clinical research on depression.The episode also explores preliminary Parkinson’s and Alzheimer’s reports, why a change in a biomarker is not the same as preventing disease, and what it would take to establish a meaningful benefit for older adults.The verdict: psilocybin deserves serious investigation. The evidence discussed does not establish human life extension or dementia prevention. Its strongest clinical argument remains mental health treatment in carefully supervised settings.🔑 KEYWORDSPsilocybin • Psilocin • Psychedelics • Longevity • Brain Plasticity • Depression • Inflammation • Cognitive Aging • ReProgram Scorecard📌 KEY TAKEAWAYS• The longevity headline needs context. More cell divisions in a dish and improved mouse survival at a study endpoint do not demonstrate longer human life.• Brain changes are measurable. Plasticity and altered network coordination do not establish a universal neurotransmitter reset or a rejuvenated brain.• Inflammation findings vary. The marker, population and timing matter; sustained clinical benefit remains an open question.• Preliminary observations cannot establish dementia prevention. Small uncontrolled studies and an Alzheimer’s case report provide research questions, not proof of disease reversal.• Mental health benefits deserve their own assessment. Randomized evidence is encouraging, while durability, patient selection, support and adverse effects still matter.• Evidence grades are claim specific. A strong plasticity score cannot fill the evidence gap for dementia prevention or human life extension.🎙️ THE REPROGRAM PERSPECTIVEPsilocybin’s potential is worth investigating. The next step is to establish which changes help, who benefits, how long benefits last, and what they cost in risk.Brain plasticity and network change: 4/5Mental health benefit in supervised treatment: 3/5Reducing inflammation: 2/5Preventing cognitive decline: 1/5Extending human lifespan: 1/5These are evidence grades, not treatment recommendations. They are not averaged into an overall score. The episode does not establish a longevity dosing regimen or justify self-directed use.⏱️ CHAPTERS00:00 Could psilocybin change how we age?01:12 Five different claims01:54 Cells mice and the longevity headline03:19 What brain plasticity actually means05:06 Human brain changes and study limitations05:52 Neurotransmitters and the chemical reset claim07:00 Inflammation signals and conflicting findings09:00 Cognitive decline Parkinson's and Alzheimer's10:58 Depression benefits durability and risks11:59 The five part ReProgram Scorecard13:26 What would change the evidence grades14:03 Safety and the final verdict📝 SELECTED NOTES AND REFERENCES1. Psilocybin treatment extends cellular lifespan and improves survival of aged mice. npj Aging. 2025. Cell and aged female mouse experiments behind the longevity discussion.https://doi.org/10.1038/s41514-025-00...2. Psilocybin desynchronizes the human brain. Nature. 2024. Repeated imaging of brain network changes in seven healthy adults.https://doi.org/10.1038/s41586-024-07...3. Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks. Cell. Published online December 2025. Mouse research on activity-dependent plasticity.https://doi.org/10.1016/j.cell.2025.1...If you value longevity science without the hype, subscribe to The ReProgram.Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

ReProgram Episode 26: GLP-1 Drugs for Longevity🎬 EPISODE OVERVIEWA drug millions of people already take extended median lifespan by approximately 12% in older female mice. Does that change the case for GLP-1 drugs as longevity therapies?In this update, Dr. George Murphy reopens The ReProgram Scorecard to examine a new Nature study of late-life semaglutide treatment. He explores the survival findings, improvements in physical and cognitive performance, and the questions that determine how broadly we should interpret the results.How long did the control animals live? How much of the benefit came from eating less? What can a study conducted in females tell us about males—and ultimately humans?The episode also examines new research connecting calorie restriction with DNA mutation accumulation, the challenge of translating mouse biology into human outcomes, and the lessons from semaglutide’s Alzheimer’s trials.The updated assessment: stronger animal evidence and more compelling questions, while the overall grade remains B+.🔑 KEYWORDSGLP-1 • Semaglutide • Ozempic • Wegovy • Longevity • Healthy Aging • Calorie Restriction • Somatic Mutations • Healthspan • ReProgram Scorecard📌 KEY TAKEAWAYS• The survival finding deserves attention. Median lifespan increased from 742 to 834 days when semaglutide treatment began at 20 months of age and continued throughout life.• The calorie restriction question remains open. Selected functional outcomes were compared with matched calorie restriction; lifespan was not.• A benefit in females does not establish a female-specific effect. Males were not tested.• Historical controls provide context. They cannot replace the controls studied alongside treated animals; replication remains essential.• The DNA connection is a hypothesis. New calorie restriction research raises questions about mutation accumulation, but does not establish that semaglutide reduces somatic mutations.• Human outcomes still determine the grade. Strength, mobility, nutrition, cognition, and independence remain central to evaluating longevity interventions.🎙️ THE REPROGRAM PERSPECTIVEThis study strengthens the reason to investigate GLP-1 therapies in aging. It also sharpens the experiments we need next: replication, direct survival comparisons with calorie restriction, testing both sexes, and meaningful human outcomes.Mechanistic plausibility remains 4.5/5. Human evidence remains 3.5/5. The overall grade stays B+.My interest has increased. My standard of evidence has not changed.⏱️ CHAPTERS00:00 A 12% Lifespan Increase: What Does It Mean?00:36 Revisiting GLP1 Therapies and Longevity01:12 The New Nature Study01:28 How Semaglutide Works01:57 The Survival Result03:10 The Importance of Starting Age in Treatment03:57 The Control-Lifespan Debate05:33 Sex Differences in Longevity Research06:26 The Calorie Restriction Question07:35 Calorie Restriction & DNA Mutations09:01 Translating Mouse Findings to Humans10:00 Lessons from the Alzheimer’s Trials11:02 The Updated ReProgram Scorecard📝 NOTES AND REFERENCES1. Feng Y, et al. Late-life semaglutide treatment slows ageing and extends lifespan in female mice. Nature. 2026;657:469–476. The central study discussed in this episode.https://www.nature.com/articles/s41586-026-10940-72. Grońska-Pęski M, et al. Caloric restriction modulates genome-wide somatic mutation in mice. Cell. 2026. The calorie restriction and mutation study discussed in the episode.https://doi.org/10.1016/j.cell.2026.08.0133. Harrison DE, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392–395. A landmark comparison showing that late-life intervention can extend lifespan in both sexes.https://www.nature.com/articles/nature08221If you value longevity science without the hype, subscribe to The ReProgram.Mechanism over marketing. Evidence over anecdotes. Trade-offs over hype.Knowledge is power.

ReProgram Episode 25: 🩸 YOUR BLOOD MAY BE AGING BEFORE YOU ARE🧠 Episode OverviewBlood aging is often overlooked, but the hematopoietic stem cells inside your bone marrow carry a decades-long history.Your blood is not just a fluid; it is a continuously renewing organ system. As the stem cells that manufacture your blood cells age, they can shift immune composition and increase susceptibility to inflammation. This process is central to understanding how systemic aging actually unfolds, moving beyond simple protein panels or biological clocks to look at the cellular machinery that sustains you.We examine the reality of clonal hematopoiesis, known as CHIP, and why it acts as a risk marker rather than a diagnosis. By separating mechanism from marketing, we clarify what parabiosis experiments and plasma exchange can—and cannot—actually achieve in human biology. Understanding blood aging helps us prioritize evidence-based outcomes over the hype of rejuvenation.Subscribe to The ReProgram for scientist-led longevity biology breakdowns, and let us know in the comments if you want a deeper look at specific plasma-related interventions.#BloodAging #LongevityScience #HealthyAging #TheReProgram🎙️ The ReProgram PerspectiveBlood aging forces us to rethink a familiar assumption. The cells circulating today may be new, but their factory - the hematopoietic stem-cell system and its marrow niche - has been shaped by decades of stress, inflammation, mutation, and repair.The biology is compelling because it connects systems that are often discussed separately: immunity, cancer risk, vascular inflammation, tissue repair, and aging. CHIP is a particularly powerful example. A mutation beginning in one stem cell can eventually influence enormous numbers of immune cells and potentially affect organs far beyond the bone marrow.But risk is not destiny, and mechanism is not treatment. CHIP should not be treated as leukemia, a mouse rejuvenation experiment should not be presented as a human anti-aging therapy, and a change in circulating proteins or an aging clock should not be confused with better function, fewer diseases, or longer life.The standard for a credible rejuvenation intervention should be transparent: disclose the intervention, pre-register the trial, define clinically meaningful outcomes, use appropriate controls, report adverse events, and publish the full results. Longevity science moves forward when fascinating biology is tested with standards strong enough to survive the hype around it.Office Artifact On the desk: GIANT MICROBES Blood Cells⏱️ Chapters00:00 The Blood Factory: Understanding Blood Cell Production01:26 Aging Blood: Impacts on Health and Disease02:38 The Role of Stem Cells in Blood Renewal06:23 Immune Aging: The Complexity of Immune Responses08:07 Clonal Hematopoiesis: A New Layer of Blood Aging10:16 The Link Between Blood Aging and Cardiovascular Disease12:52 Restoring Youth: Potential Strategies for Blood Rejuvenation16:52 Parabiosis: The Young Blood Experiment19:40 Plasma exchange: biology versus hype21:15 Emerging Treatments: The One Generation Approach25:09 Practical Takeaways: Managing Blood Health